ATE224454T1 - Drei hybriden screening test - Google Patents

Drei hybriden screening test

Info

Publication number
ATE224454T1
ATE224454T1 AT97921370T AT97921370T ATE224454T1 AT E224454 T1 ATE224454 T1 AT E224454T1 AT 97921370 T AT97921370 T AT 97921370T AT 97921370 T AT97921370 T AT 97921370T AT E224454 T1 ATE224454 T1 AT E224454T1
Authority
AT
Austria
Prior art keywords
hybrid
ligand
protein
small molecules
unknown
Prior art date
Application number
AT97921370T
Other languages
English (en)
Inventor
Jun Liu
Edward J Licitra
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE224454T1 publication Critical patent/ATE224454T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Peptides Or Proteins (AREA)
AT97921370T 1996-04-26 1997-04-25 Drei hybriden screening test ATE224454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1734196P 1996-04-26 1996-04-26
PCT/US1997/006912 WO1997041255A1 (en) 1996-04-26 1997-04-25 Three-hybrid screening assay

Publications (1)

Publication Number Publication Date
ATE224454T1 true ATE224454T1 (de) 2002-10-15

Family

ID=21782024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97921370T ATE224454T1 (de) 1996-04-26 1997-04-25 Drei hybriden screening test

Country Status (8)

Country Link
US (1) US5928868A (de)
EP (1) EP0907750B1 (de)
JP (1) JP2000508923A (de)
AT (1) ATE224454T1 (de)
CA (1) CA2252886C (de)
DE (1) DE69715621T2 (de)
ES (1) ES2183166T3 (de)
WO (1) WO1997041255A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891021B2 (en) * 1993-02-12 2005-05-10 Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
US6972193B1 (en) * 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US6841347B1 (en) * 1998-02-05 2005-01-11 The General Hospital Corporation In vivo construction of DNA libraries
US6187535B1 (en) 1998-02-18 2001-02-13 Institut Pasteur Fast and exhaustive method for selecting a prey polypeptide interacting with a bait polypeptide of interest: application to the construction of maps of interactors polypeptides
WO1999067639A1 (en) * 1998-06-25 1999-12-29 Caliper Technologies Corporation High throughput methods, systems and apparatus for performing cell based screening assays
CA2338247A1 (en) * 1998-07-28 2000-02-10 Vimal D. Mehta General screening method for ligand-protein interactions
EP1792989A1 (de) 1999-04-12 2007-06-06 Agensys, Inc. 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
AU780061B2 (en) 1999-04-12 2005-02-24 Agensys, Inc. Transmembrane protein expressed in prostate and other cancers
US20060073150A1 (en) 2001-09-06 2006-04-06 Mary Faris Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
JP4373637B2 (ja) 1999-08-12 2009-11-25 アジェンシス，インコーポレイテッド ヒト前立腺癌において発現されるｃ型レクチン膜貫通抗原およびその使用
CA2385032C (en) 1999-10-05 2013-12-10 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
EP1244810B1 (de) * 2000-01-06 2008-02-20 Caliper Life Sciences, Inc. Methoden und syteme zur überwachung intrazellulärer bindereaktionen
US20020004202A1 (en) * 2000-01-24 2002-01-10 Cornish Virginia W. In vivo screen using chemical inducers of dimerization
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US6410246B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Highly diverse library of yeast expression vectors
AU2002218786A1 (en) 2000-07-12 2002-01-21 Agensys, Inc. Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers
AU2001285210A1 (en) 2000-08-22 2002-03-04 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
ATE403716T1 (de) 2000-08-28 2008-08-15 Agensys Inc Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
HRP20010018A2 (en) 2001-01-09 2002-12-31 Pliva D D Novel anti-inflammatory compounds
US20020168737A1 (en) * 2001-01-24 2002-11-14 Cornish Virginia W. Binding and catalysis screen for high throughput determination of protein function using chemical inducers of dimerization
US20030165873A1 (en) * 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
CA2444857A1 (en) * 2001-04-20 2002-10-31 President And Fellows Of Harvard College Compositions and methods for the identification of protein interactions in vertebrate cells
AU2002358520A1 (en) * 2001-11-28 2003-06-10 Graffinity Pharmaceuticals Ag Method for the selection and identification of peptide or protein molecules by means of phase display
DE10220593A1 (de) * 2001-11-28 2003-06-12 Graffinity Pharmaceuticals Ag SPR-Sensorflächenträger
WO2003046526A1 (de) * 2001-11-28 2003-06-05 Graffinity Pharmaceuticals Ag Spr-sensorflächenträger
US20030138785A1 (en) * 2001-12-21 2003-07-24 Stephan Kopytek In vivo protein screen based on enzyme-assisted chemically induced dimerization ("CID")
US7271154B2 (en) * 2002-02-15 2007-09-18 Merckle Gmbh Antibiotic conjugates
US20040186063A1 (en) * 2002-02-15 2004-09-23 Hans-Jurgen Gutke Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003219770B2 (en) * 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US20040005641A1 (en) * 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7083918B2 (en) * 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
JP4790263B2 (ja) * 2002-07-08 2011-10-12 グラクソ グループ リミテッド 炎症性の疾患および病態を治療する新規な化合物、組成物および方法
JP2005536488A (ja) 2002-07-08 2005-12-02 プリヴァ−イストラジヴァキ・インスティトゥ・ディー・オー・オー 新規な非ステロイド抗炎症物質、組成物、およびその使用方法
US7157433B2 (en) 2002-07-08 2007-01-02 Glaxosmithkline Istrazivacki Centar Zagreb Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules
JP2005532071A (ja) * 2002-07-10 2005-10-27 ストラタジーン カリフォルニア 足場としてのヒト化レニラ・レニフォルミス緑色蛍光タンパク質
US20040067532A1 (en) * 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2515699C (en) 2003-02-10 2015-01-27 Aya Jakobovits Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
NZ572940A (en) 2003-05-30 2010-04-30 Agensys Inc Prostate stem cell antigen (PSCA) variants and subsequences thereof
JP4651663B2 (ja) 2004-05-28 2011-03-16 アジェンシス，インコーポレイテッド Ｐｓｃａタンパク質に結合する抗体および関連分子
US8034553B2 (en) 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
CA2570825A1 (en) * 2004-07-16 2006-01-26 Novartis Ag Use of a steroid for enhancement of skin permeability
CA2586182A1 (en) * 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. Method of gene screening with yeast that inducibly expresses ergosterol biosynthetic enzyme
JP2008537483A (ja) 2005-03-15 2008-09-18 イノジェネティックス・ナムローゼ・フェンノートシャップ ヌクレオシドアナログに対する感受性を低減したｂ型肝炎ウイルス変種およびその使用
EP2444099A1 (de) 2005-03-31 2012-04-25 Agensys, Inc. An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
CN101228171A (zh) * 2005-07-26 2008-07-23 默克勒有限公司 作为5-脂氧化酶和环加氧酶抑制剂的吡咯里嗪和中氮茚化合物的大环内酯偶联物
JP5346583B2 (ja) * 2005-09-28 2013-11-20 アッタゲネ インコーポレーテッド 生物検体の生物活性を解析するための方法及び構築物、並びに生物の状態を測定するための方法及び構築物
WO2007042771A1 (en) * 2005-10-10 2007-04-19 Astrazeneca Ab Three hybrid screening assay using reverse transfected mammalian cell arrays
EP2193146B1 (de) 2007-09-14 2016-05-25 Adimab, LLC Synthetische antikörperbibliotheken mit rationalem design und ihre verwendung
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20090162858A1 (en) * 2007-09-18 2009-06-25 Cornish Virginia W Orthogonal chemical inducer of dimerization
CN101131363B (zh) * 2007-09-30 2010-12-01 南京大学 一种基于酵母三杂交的小分子化合物检测方法
EP3741883B1 (de) 2010-07-16 2022-12-14 Adimab, LLC Antikörperbibliotheken

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004321A1 (en) * 1989-09-25 1991-04-04 President And Fellows Of Harvard College Receptor for fk-506
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5115098A (en) * 1990-02-28 1992-05-19 President And Fellows Of Harvard College End-blocked peptides inhibiting binding capacity of gp120
US5362629A (en) * 1991-08-05 1994-11-08 President And Fellows Of Harvard College Detection of immunosuppressants
US5498597A (en) * 1992-01-17 1996-03-12 Dana-Farber Cancer Institute, Inc. FKBP-13, an FK506-binding immunophilin
PL310327A1 (en) * 1993-02-12 1995-12-11 Univ Leland Stanford Junior Adjustable transcription of target genes and other biological processes
WO1994023025A1 (en) * 1993-03-31 1994-10-13 Cadus Pharmaceuticals, Inc. Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
AU696991B2 (en) * 1993-07-16 1998-09-24 Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
AU2159895A (en) * 1994-03-11 1995-09-25 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
EP0758392A1 (de) * 1994-04-26 1997-02-19 Cadus Pharmaceutical Corporation Die expression von funktionaler, menschlicher adenylyl-cyclase in hefe
US5989808A (en) * 1994-06-14 1999-11-23 American Cyanamid Company Identification of compounds affecting specific interaction of peptide binding pairs
EP0773952B1 (de) * 1994-07-20 2003-11-12 The General Hospital Corporation Interaktions-fullensysteme zum nachweis von protein-interaktionen
DE69534300T2 (de) * 1994-08-18 2006-05-18 Ariad Gene Therapeutics, Inc., Cambridge Neues multimerisierendes reagenz
JPH10507624A (ja) * 1994-08-18 1998-07-28 アリアド・ジーン・セラピューティクス・インコーポレーテッド 遺伝子発現、遺伝子産物機能および工学処理された宿主細胞の調節可能な除去
ATE307899T1 (de) * 1994-11-01 2005-11-15 Ariad Gene Therapeutics Inc Neue methode zum auffindenund bewerten biologisch aktiver moleküle
US5610015A (en) * 1995-03-23 1997-03-11 Wisconsin Alumni Research Foundation System to detect protein-RNA interactions

Also Published As

Publication number Publication date
CA2252886C (en) 2008-02-12
DE69715621T2 (de) 2003-05-22
US5928868A (en) 1999-07-27
EP0907750B1 (de) 2002-09-18
WO1997041255A1 (en) 1997-11-06
EP0907750A1 (de) 1999-04-14
ES2183166T3 (es) 2003-03-16
CA2252886A1 (en) 1997-11-06
DE69715621D1 (de) 2002-10-24
JP2000508923A (ja) 2000-07-18

Similar Documents

Publication Publication Date Title
DE69715621D1 (de) Drei hybriden screening test
Melby et al. High sensitivity top–down proteomics captures single muscle cell heterogeneity in large proteoforms
Gygi et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology
Zieske A perspective on the use of iTRAQ™ reagent technology for protein complex and profiling studies
Natsume et al. A direct nanoflow liquid chromatography− tandem mass spectrometry system for interaction proteomics
Tang et al. A new cross-linking strategy: protein interaction reporter (PIR) technology for protein–protein interaction studies
Rai et al. Cancer proteomics: serum diagnostics for tumor marker discovery
Sannino et al. Quantitative Assessment of Affinity Selection Performance by Using DNA‐Encoded Chemical Libraries
Murphy et al. Clathrin assembly protein AP-3: The identity of the 155K protein, AP 180, and NP185 and demonstration of a clathrin binding domain
Righetti et al. The proteome: anno Domini 2002.
DE69308842D1 (de) Testsätze von peptid-unterbibliotheken
Maccarrone et al. Characterization of a protein interactome by co-immunoprecipitation and shotgun mass spectrometry
DE69938623D1 (de) Microarrays und ihre verwendungen
PT765389E (pt) Novos sistemas celulares tendo interaccao especifica de pares de peptidicos que se ligam mutuamente
Pernemalm et al. Use of narrow‐range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion
JPH1025299A (ja) 整列ペプチド、及びそれを用いたタンパク質の結合・相互作用部位検出方法
Moussavi-Harami et al. Characterization of molecules binding to the 70K N-terminal region of fibronectin by IFAST purification coupled with mass spectrometry
Brown et al. Direct seminal fluid identification by protease‐free high‐resolution mass spectrometry
Lee et al. Proteomic analysis of chromatin-modifying complexes in Saccharomyces cerevisiae identifies novel subunits
Preisinger et al. Proteomics and phosphoproteomics for the mapping of cellular signalling networks
Lim Kam Sian et al. SAPrIm, a semi-automated protocol for mid-throughput immunopeptidomics
Boraldi et al. Normal human dermal fibroblasts: proteomic analysis of cell layer and culture medium
DE60034966D1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
Tan et al. Detection of DNA adducts of benzo [a] pyrene using immunoelectrophoresis with laser-induced fluorescence: Analysis of A549 cells
DE69525366D1 (de) Die verwendung von bmp-protein-rezeptor komplexen für das screening von substanzen aus dem knochenmetabolismus und zellen die mit einem typ i- und typ ii-bmp-rezeptor co-transfiziertsind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0907750

Country of ref document: EP

REN Ceased due to non-payment of the annual fee